EUVIMEDOpdag EUVIMED
EUVIMED · CrossrefJournal

EJC Skin Cancer

ISSN 2772-6118 · Elsevier BV

Latest articles

  1. Erratum to “Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study” [EJC Skin Cancer 4 (2026) 100773]

    Eva Ellebaek, Michael Weichenthal, Iva Gavrilova, Nethanel Asher, Patrick Terheyden, Jochen Utikal, Amina Jalovčić Suljeviić, Claudia Pföhler, Igor Stojkovski, Rudolf Alexander Herbst, Selma Ugurel, Christina Ruhlmann, Alfonso Berrocal, Margarita Majem, Branko Dujovic, Viktor Šabarić, Tomislav Duvancic, Ainara Soria, Marco Donia, Henrik Schmidt, Rasmus B. Friis, Alexander Gerasimov, Gergana Shalamanova-Deleva, Ahmed Kontilev, Shaked Lev-Ari, Ronnie Shapira, Luisa Piccin, Alessandro Minisini, Berna C. Özdemir, Pawel Teterycz, Anna Mariuk-Jarema, Dimitrios Ziogas, Amalia Anastasopoulou, Dimitra Stefanou, Lourdes Gutiérrez, Christoffer Gebhardt, Reinhard Dummer, Axel Hauschild, Peter Mohr, Imke von Wasielewski

    Published: 2026-04DOI: 10.1016/j.ejcskn.2026.101130

  2. Erratum to “Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma” [EJC Skin Cancer 3 (2025) 100284]

    Oliver John Kennedy, Nina Glassee, Michal Kicinski, Emanuel Bührer, Sara Valpione, Sara Gandini, Stefan Suciu, Christian U. Blank, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye Boers-Sonderen, Anna Maria Di Giacomo, Alfonsus J.M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala

    Published: 2026-04DOI: 10.1016/j.ejcskn.2026.101134

  3. Erratum to: “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727]

    Emanuel Bührer, Nina Glassee, Michal Kicinski, Oliver J. Kennedy, Christian U. Blank, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye Boers-Sonderen, Anna Maria Di Giacomo, Alfonsus J.M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala

    Published: 2026-04DOI: 10.1016/j.ejcskn.2026.101140

  4. Erratum to “CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review” [EJC Skin Cancer 1 (2023) 100005]

    SvenjaVanessa Wiedemann, Verena Müller, Bettina Toth, Michael Erdmann, Bodo Bühler, Susanne Dugas-Breit, Kerstin Schatton, Lydia Reinhardt, Markus Meissner, Marion Mickler, Claudia Pföhler, Carsten Weishaupt, Rudolf Herbst, Dirk Debus, Laura Susok, Katharina Tietze Julia, Julia Welzel, Andreas Arnold, Evelyn Dabrowski, Andrea Forschner, Steven Goetze, Kinan Hayani, Céleste Lebbe, Florian Löhr, Miriam Mengoni, Barbara Hermes, Wiebke Katharina Peitsch, Gabriela Poch, Michael Max Sachse, Anca Sindrilaru, Saskia Wenk, Mirjana Ziemer, Kjell Kaune, Lisette Meier-Naust, Georgios Nikolakis, Florian Oberndörfer, Ulrich Wesselmann, Jochen Sven Utikal, Maria Rita Gaiser

    Published: 2026-03DOI: 10.1016/j.ejcskn.2026.100784

  5. Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727]

    Emanuel Bührer, Nina Glassee, Michal Kicinski, Oliver J. Kennedy, Christian U. Blank, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye Boers-Sonderen, Anna Maria Di Giacomo, Alfonsus J.M. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala

    Published: 2026-03DOI: 10.1016/j.ejcskn.2026.101132

  6. BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter study

    Michael Weichenthal, Iva Gavrilova, Peter Mohr, Berna C. Özdemir, Nethanel Asher, Eva Ellebaek, Jens Ulrich, Alexander Kreuter, Aleksander Popovic, Christina Ruhlmann, Igor Stojkovski, Shaked Lev-Ari, Edgar Dippel, Almudena García Castaño, Lorena Bellido Hernández, Henrik Schmidt, Egle Ramelyte, Dimitrios Ziogas, Luisa Piccin, Katarzyna Kozak, Dirk Debus, Gergana Shalamanova-Deleva, Ronnie Shapira, John Haanen, Inge Marie Svane, Paolo A. Ascierto, Piotr Rutkowski, Helen Gogas, Joanna Mangana, Lars Bastholt, Dirk Schadendorf

    Published: 2026DOI: 10.1016/j.ejcskn.2026.100776

  7. A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3)

    C. Robert, Y.G. Najjar, N.I. Khushalani, M.K. Wong, T.L. Bowles, P.A. Ascierto, G.V. Long, D. Schadendorf, A. Betof, G.A. Daniels, G.K. In, F. Collichio, A. Davarifar, Y. Saenger, S. Rapisuwon, R.M. Weight, G. Gullo, M. Viana, M. Navarro, O. Hamid

    Published: 2026DOI: 10.1016/j.ejcskn.2026.100791

  8. Adjuvant therapy with locoregional interferon-beta versus surgery alone for resected stage II/III cutaneous melanoma: A multicenter randomized phase III trial (JCOG1309, J-FERON)

    K. Namikawa, D. Ogata, M. Yokoyama, Y. Sano, H. Fukuda, A. Takahashi, T. Takenouchi, Y. Nakamura, S. Yoshikawa, A. Hiura, H. Uchi, A. Tsutsumida, J. Uehara, K. Yoshino, Y. Shibayama, S. Fukushima, E. Nakano, Y. Nakamura, Y. Kiniwa, M. Aoki, H. Uhara, N. Hatta, D. Yamada, T. Hayashi, S. Matsushita, J. Omatsu, K. Yamamura, T. Miyagawa, N. Yamazaki

    Published: 2026DOI: 10.1016/j.ejcskn.2026.100796

  9. Biomarker and updated clinical data for RP1 plus nivolumab in anti–PD-1–failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade

    C. Robert, P.K. Bommareddy, T.M. Wise-Draper, J.J. Sacco, G.K. In, E. Muñoz Couselo, D. Schadendorf, J. Niu, G.M. Beasley, B. Chmielowski, M.M. Milhem, T.L. Bowles, K.K. Tsai, C. Lebbé, C. Gaudy-Marqueste, A. Samson, J. Zhu, M. Viana, C. Tucci, B. Paratala, J.W. Hou, M.K. Wong

    Published: 2026DOI: 10.1016/j.ejcskn.2026.100800

Volumes

2026 · 3982025 · 4892024 · 2602023 · 11

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.